跳至主要内容
临床试验/NL-OMON52406
NL-OMON52406招募中不适用

Morphine or Fentanyl for Refractory dyspnea in COPD - MoreFoRCOPD

niversitair Medisch Centrum Groningen0 个研究点目标入组 60 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
60

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • Age >=40 years
  • Read, understood and signed the Informed Consent form
  • COPD GOLD class III or IV, according to GOLD criteria.
  • - Post-bronchodilatation FEV1/FVC < 70% and FEV1 < 50% pred.
  • Complaints of refractory dyspnea as established by patient and doctor.
  • mMRC score >= 3.
  • Life expectancy of >= 2 months.
  • Optimized standard therapy according to Dutch LAN guideline for diagnosis and
  • treatment of COPD.

排除标准

  • Other severe disease with chronic pain or chronic dyspnea (a non-susbstantial
  • component of left sided heart failure is acceptable).
  • Current use of opioids for whatever indication
  • Allergy / intolerance for opioids
  • Psychiatric disease, not related to severe COPD.
  • Exacerbation of COPD eight weeks prior to inclusion or between screening and
  • randomization.
  • Problematic (leading to medical help or social problems) substance abuse
  • during the last five years.
  • Active malignancy, with the exception of planocellular or basal cell
  • carcinoma of the skin.
  • eGFR 15 ml/min

研究者

相似试验